Incannex Healthcare Limited is a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs. Incannex Healthcare Limited is based in MELBOURNE, Australia.
| Revenue (Most Recent Fiscal Year) | $0.01M |
| Net Income (Most Recent Fiscal Year) | $-18.46M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.53 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -22156.12% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -342.92% |
| Return on Assets (Trailing 12 Months) | -148.64% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.12 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.12 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.25 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.24 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.15 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.21 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 29.43M |
| Free Float | 21.62M |
| Market Capitalization | $6.48M |
| Average Volume (Last 20 Days) | 66.05M |
| Beta (Past 60 Months) | 7.67 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 26.53% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.43% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |